MYD88 and diffuse large B-cell lymphoma: Recent studies have demonstrated the potential superior antitumor activity of these compounds in combination with ibrutinib, bortezomib, or venetoclax in preclinical models of WM, MYD88-mutated DLBCL, and CLL [104,105,106,107,108].